Compare Orchid Chemicals with - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs ALKEM LABORATORIES - Comparison Results

ORCHID PHARMA LTD     Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD ALKEM LABORATORIES ORCHID PHARMA LTD/
ALKEM LABORATORIES
 
P/E (TTM) x -0.5 - - View Chart
P/BV x 0.1 6.6 1.8% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 ORCHID PHARMA LTD   ALKEM LABORATORIES
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
ALKEM LABORATORIES
Mar-16
ORCHID PHARMA LTD/
ALKEM LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1941,589 12.2%   
Low Rs351,232 2.8%   
Sales per share (Unadj.) Rs276.5417.5 66.2%  
Earnings per share (Unadj.) Rs-79.256.3 -140.7%  
Cash flow per share (Unadj.) Rs-43.564.7 -67.2%  
Dividends per share (Unadj.) Rs012.70 0.0%  
Dividend yield (eoy) %00.9 0.0%  
Book value per share (Unadj.) Rs53.9292.9 18.4%  
Shares outstanding (eoy) m70.45119.57 58.9%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.43.4 12.3%   
Avg P/E ratio x-1.425.1 -5.8%  
P/CF ratio (eoy) x-2.621.8 -12.1%  
Price / Book Value ratio x2.14.8 44.1%  
Dividend payout %022.6 0.0%   
Avg Mkt Cap Rs m8,067168,653 4.8%   
No. of employees `0002.8NA-   
Total wages/salary Rs m2,5279,171 27.6%   
Avg. sales/employee Rs Th6,956.1NM-  
Avg. wages/employee Rs Th902.5NM-  
Avg. net profit/employee Rs Th-1,993.0NM-  
INCOME DATA
Net Sales Rs m19,47749,915 39.0%  
Other income Rs m4071,645 24.8%   
Total revenues Rs m19,88451,561 38.6%   
Gross profit Rs m1,1038,482 13.0%  
Depreciation Rs m2,5191,006 250.5%   
Interest Rs m5,227671 779.4%   
Profit before tax Rs m-6,2368,451 -73.8%   
Minority Interest Rs m20-114 -17.3%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-1251,606 -7.8%   
Profit after tax Rs m-5,5806,731 -82.9%  
Gross profit margin %5.717.0 33.3%  
Effective tax rate %2.019.0 10.6%   
Net profit margin %-28.713.5 -212.5%  
BALANCE SHEET DATA
Current assets Rs m11,01427,062 40.7%   
Current liabilities Rs m32,06015,324 209.2%   
Net working cap to sales %-108.123.5 -459.5%  
Current ratio x0.31.8 19.5%  
Inventory Days Days9567 142.7%  
Debtors Days Days3441 81.3%  
Net fixed assets Rs m29,44012,610 233.5%   
Share capital Rs m705239 294.6%   
"Free" reserves Rs m2,04334,490 5.9%   
Net worth Rs m3,80035,027 10.8%   
Long term debt Rs m9,0181,212 744.3%   
Total assets Rs m46,51054,387 85.5%  
Interest coverage x-0.213.6 -1.4%   
Debt to equity ratio x2.40 6,860.7%  
Sales to assets ratio x0.40.9 45.6%   
Return on assets %-0.813.6 -5.6%  
Return on equity %-146.919.2 -764.2%  
Return on capital %-3.724.9 -15.0%  
Exports to sales %37.912.9 292.6%   
Imports to sales %22.63.1 733.1%   
Exports (fob) Rs m7,3786,461 114.2%   
Imports (cif) Rs m4,4061,540 286.1%   
Fx inflow Rs m7,5136,563 114.5%   
Fx outflow Rs m5,6493,012 187.6%   
Net fx Rs m1,8653,552 52.5%   
CASH FLOW
From Operations Rs m1,6827,259 23.2%  
From Investments Rs m-9,8601,864 -528.9%  
From Financial Activity Rs m6,644-9,273 -71.6%  
Net Cashflow Rs m-1,535-150 1,023.3%  

Share Holding

Indian Promoters % 32.3 66.9 48.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.6 33.1 13.9%  
FIIs % 3.3 0.0 -  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 0.0 -  
Shareholders   84,811 68,381 124.0%  
Pledged promoter(s) holding % 54.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   GLENMARK PHARMA  FULFORD INDIA  DR. REDDYS LAB  DIVIS LABORATORIES  UNICHEM LAB  

Compare ORCHID PHARMA LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

ORCHID PHARMA LTD Announces Quarterly Results (2QFY19); Net Profit Up 67.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended September 2018, ORCHID PHARMA LTD has posted a net profit of Rs 231 m (up 67.1% YoY). Sales on the other hand came in at Rs 1 bn (down 31.9% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

ORCHID PHARMA LTD Announces Quarterly Results (4QFY18); Net Profit Up 50.8% (Quarterly Result Update)

Aug 24, 2018 | Updated on Aug 24, 2018

For the quarter ended March 2018, ORCHID PHARMA LTD has posted a net profit of Rs 924 m (up 50.8% YoY). Sales on the other hand came in at Rs 2 bn (down 24.0% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Jul 24, 2019 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD - PFIZER COMPARISON

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS